PT658118E - Vacinas contra neisseria meningitidis do grupo c - Google Patents

Vacinas contra neisseria meningitidis do grupo c

Info

Publication number
PT658118E
PT658118E PT93921251T PT93921251T PT658118E PT 658118 E PT658118 E PT 658118E PT 93921251 T PT93921251 T PT 93921251T PT 93921251 T PT93921251 T PT 93921251T PT 658118 E PT658118 E PT 658118E
Authority
PT
Portugal
Prior art keywords
gcmp
group
conjugate
modified
neisseria meningitidis
Prior art date
Application number
PT93921251T
Other languages
English (en)
Inventor
Harold Jennings
Joseph Y Tai
Francis Michon
Lucjan J J Hronowski
Sharon Mates
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/938,367 external-priority patent/US5425946A/en
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Publication of PT658118E publication Critical patent/PT658118E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PT93921251T 1992-08-31 1993-08-30 Vacinas contra neisseria meningitidis do grupo c PT658118E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/938,367 US5425946A (en) 1992-08-31 1992-08-31 Vaccines against group C Neisseria meningitidis
US6450193A 1993-05-19 1993-05-19

Publications (1)

Publication Number Publication Date
PT658118E true PT658118E (pt) 2002-05-31

Family

ID=26744584

Family Applications (1)

Application Number Title Priority Date Filing Date
PT93921251T PT658118E (pt) 1992-08-31 1993-08-30 Vacinas contra neisseria meningitidis do grupo c

Country Status (12)

Country Link
EP (1) EP0658118B1 (pt)
JP (2) JP4097691B2 (pt)
AT (1) ATE212233T1 (pt)
AU (1) AU4841693A (pt)
CA (1) CA2142981C (pt)
DE (1) DE69331495T2 (pt)
DK (1) DK0658118T3 (pt)
ES (1) ES2171418T3 (pt)
NO (1) NO323616B1 (pt)
PL (1) PL175595B1 (pt)
PT (1) PT658118E (pt)
WO (1) WO1994005325A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780606A (en) * 1995-06-07 1998-07-14 Connaught Laboratories Limited Neisseria meningitidis capsular polysaccharide conjugates
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP0994723A1 (en) * 1997-06-24 2000-04-26 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
US7749511B2 (en) 2000-04-18 2010-07-06 Endobiologics, Incorporated Anti-sepsis conjugate vaccine
WO2001078787A2 (en) * 2000-04-18 2001-10-25 Endobiologics, Incorporated Lipopolysaccharide-conjugate vaccine for sepsis treatment
RO122761B1 (ro) * 2001-01-23 2010-01-29 Aventis Pasteur Vaccin multivalent antimeningococic conţinând polizaharid-proteină
BRPI0411815A (pt) * 2003-06-23 2006-08-08 Baxter Int vacinas contra neisseria meningitidis do tipo y e suas combinações meningocócicas
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
RU2378010C2 (ru) 2003-10-02 2010-01-10 Новартис Вэксинес Энд Дайэгностикс С.Р.Л. Жидкие вакцины для множественных серогрупп менингококков
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
BRPI0510315A (pt) 2004-04-30 2007-10-16 Chiron Srl integração de vacinação com conjugado meningocócico
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
SI2004225T1 (sl) 2006-03-22 2012-08-31 Novartis Ag Reĺ˝imi za imunizacijo z meningokoknimi konjugati
US20100203137A1 (en) 2007-06-04 2010-08-12 Mario Contorni Formulation of meningitis vaccines
CA2702871A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
CN102300585A (zh) 2008-12-17 2011-12-28 诺华有限公司 包含血红蛋白受体的脑膜炎球菌疫苗
CN102256619A (zh) * 2008-12-22 2011-11-23 奥克兰儿童医院及研究中心 离体被动保护菌血症实验
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
WO2010109323A1 (en) 2009-03-24 2010-09-30 Novartis Ag Adjuvanting meningococcal factor h binding protein
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
CA2854934A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌h因子結合タンパク質のアジュバントされた組み合わせ
JP2015509963A (ja) 2012-03-08 2015-04-02 ノバルティス アーゲー Tlr4アゴニストを含む混合ワクチン
JP6324961B2 (ja) 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群b髄膜炎菌とd/t/pとの組み合わせワクチン
WO2014095771A1 (en) 2012-12-18 2014-06-26 Novartis Ag Conjugates for protecting against diphtheria and/or tetanus
KR20160040556A (ko) 2013-07-11 2016-04-14 노파르티스 아게 미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형
MY186874A (en) * 2014-02-25 2021-08-26 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd A novel downstream process for purifying polysaccharides
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.

Also Published As

Publication number Publication date
JPH08500607A (ja) 1996-01-23
EP0658118B1 (en) 2002-01-23
JP4097691B2 (ja) 2008-06-11
CA2142981C (en) 2007-10-23
PL307745A1 (en) 1995-06-12
ATE212233T1 (de) 2002-02-15
ES2171418T3 (es) 2002-09-16
CA2142981A1 (en) 1994-03-17
DE69331495D1 (de) 2002-03-14
AU4841693A (en) 1994-03-29
WO1994005325A1 (en) 1994-03-17
NO950739D0 (no) 1995-02-27
DE69331495T2 (de) 2002-10-31
EP0658118A4 (en) 1995-09-13
EP0658118A1 (en) 1995-06-21
NO950739L (no) 1995-04-26
PL175595B1 (pl) 1999-01-29
NO323616B1 (no) 2007-06-18
DK0658118T3 (da) 2002-05-06
JP2008044955A (ja) 2008-02-28

Similar Documents

Publication Publication Date Title
PT658118E (pt) Vacinas contra neisseria meningitidis do grupo c
Schneerson et al. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates
Schneerson et al. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.
ATE287947T1 (de) Orale immunisierung durch verwendung von transgenen pflanzen
ES8707861A1 (es) Un metodo para preparar un conjugado inmunogeno
RU2009134033A (ru) Жидкие вакцины для множественных серогрупп менингококков
ATE529130T1 (de) Trockenformulierung für transkutane immunisierung
DK0778781T3 (da) Pneumokok-polysaccharid-rekombinant pneumolysin-konjugat-vacciner til immunisering mod pneumokokinfektioner
NO932102L (no) Oligosakkarid avledet fra antigent polysakkarid erholdt fra et patogen
YU24391A (sh) Poboljšana meningokokna polisaharid kon-jugovana vakcina
BR9106748A (pt) Vacina de hyopneumomiae micoplasma inativado e metodo de seu uso
ES8608883A1 (es) Procedimiento de preparacion de un conjugado de muramilpeptido y de un hapteno o fragmento haptenico de bajo peso molecular.
NO995236L (no) Nerve-vekstfaktor som vaksine-adjuvant
DK341679A (da) Vaccine mod streptokokker og fremgangsmaade til fremstilling deraf
Klipstein et al. Immunological interrelationships between cholera toxin and the heat-labile and heat-stable enterotoxins of coliform bacteria
NO974727L (no) Immunogene og immunostimulatoriske oligosakkarid sammensetninger og fremgangsmåter for fremstilling derav
Eskola et al. Experience in Finland with Haemophilus influenzae type b vaccines
Somani et al. Reimmunization after allogeneic bone marrow transplantation
NO933856L (no) Pediatrisk kombinasjonsvaksine
ROBBINS et al. Haemophilus influenzae type b: the search for a vaccine
NO913131L (no) Immunogene konjugater av ikke-toksisk oligosakkarid fra bordetella pertussis lipoolysakkarid.
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
SHAMS et al. The effect of conjugation on immunogenicity and potency of protein carriers of polyribosylribitol phosphate (PRP) conjugated vaccines in the mouse model
Peeters et al. In vitro antibody response of human lymphocytes to the Haemophilus influenzae type b capsular polysaccharide
Tai et al. Vaccines against group C neisseria meningitidis